Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 27 Apr 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.